Clovis Oncology Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2022 to a ratio of 5.77, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Clovis Oncology Inc in Sep 30 2022 quarter, has decreased to 63 days, compared to 64 days, in the Jun 30 2022 quarter.

If we take a look into Healthcare sector 356 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. 2527.

What is Receivable Turnover Ratio?
What is Clovis Oncology Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLVS Receivables Turnover Ratio	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter
Y / Y Receivable Change	-24.53 %	-23.21 %	25.63 %	1.35 %	27.2 %
Y / Y Revenue Change	-19.13 %	-12.7 %	-10 %	-16.93 %	-2.21 %
Receivable Turnover Ratio (TTM)	5.77	5.7	5.57	6.04	6.36
CLVS's Total Ranking	# 2527	# 2527	# 2521	# 2651	# 2527
Accounts Receivable average collection period days	63	64	66	60	57
Seq. Receivable Change	4.76 %	-31.97 %	1.59 %	4.23 %	6.6 %
Seq. Revenue Change	-4.6 %	-6.14 %	-4.78 %	-5.14 %	2.98 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 114
Healthcare Sector	# 357
Overall Market	# 2527

Receivable Turnover Ratio Statistics
High	Average	Low
8.76	6.55	2.87
(Sep 30 2019)		(Sep 30 2017)

CLVS Company Profile • Back to CLVS Efficiency Comparisons • Compare CLVS Receivables Turnover Ratio to its Competitors

Financial Statements
Clovis Oncology Inc 's Accounts Receivable	$ 19 Millions	Visit CLVS's Balance sheet
Clovis Oncology Inc 's Sales TTM	$ 133 Millions	Visit CLVS's Income Statement
Sources of CLVS's Revenues		Visit CLVS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CLVS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CLVS's Growth Rates	CLVS's Roa	CLVS's Inventory Turnover Ratio	CLVS's Dividend Comparisons
CLVS's Profitability Ratios	CLVS's Roi	CLVS's Asset Turnover Ratio	CLVS's Dividend Growth
CLVS's Valuation Ratios	CLVS's Roe	CLVS's Financial Strength Ratios	CLVS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2022, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2022	Receivable at quarter ending Sep 30 2022
Vystar Corporation	18.33	$ 15.105 Millions	$ 0.824 Millions
Arcturus Therapeutics Holdings Inc	18.15	$ 51.500 Millions	$ 2.837 Millions
C4 Therapeutics Inc	18.09	$ 48.320 Millions	$ 2.672 Millions
Statera Biopharma Inc fka Cytocom Inc	18.01	$ 3.688 Millions	$ 0.205 Millions
Sangamo Therapeutics Inc	17.93	$ 112.055 Millions	$ 6.248 Millions
Zomedica Corp	17.70	$ 12.688 Millions	$ 0.717 Millions
Theralink Technologies Inc	17.62	$ 0.568 Millions	$ 0.032 Millions
Ainos Inc	17.57	$ 1.758 Millions	$ 0.100 Millions
Innovage Holding Corp	17.37	$ 696.788 Millions	$ 40.123 Millions
Electrocore Inc	17.28	$ 7.523 Millions	$ 0.435 Millions
Revance Therapeutics Inc	17.28	$ 108.594 Millions	$ 6.285 Millions
Strata Critical Medical Inc	17.26	$ 132.603 Millions	$ 7.682 Millions
Advanced Container Technologies Inc	17.16	$ 3.566 Millions	$ 0.208 Millions
Chemed Corporation	16.69	$ 2,139.657 Millions	$ 128.188 Millions
Ethema Health Corporation	16.39	$ 4.475 Millions	$ 0.273 Millions
Palvella Therapeutics Inc	16.17	$ 28.499 Millions	$ 1.763 Millions
Poseida Therapeutics Inc	15.68	$ 151.679 Millions	$ 9.675 Millions
Qhslab Inc	15.51	$ 1.305 Millions	$ 0.084 Millions
Endonovo Therapeutics Inc	15.04	$ 0.014 Millions	$ 0.001 Millions
Cv Sciences Inc	14.99	$ 17.305 Millions	$ 1.154 Millions
Regenxbio Inc	14.83	$ 480.034 Millions	$ 32.378 Millions
Harrow Inc	14.77	$ 88.454 Millions	$ 5.991 Millions
Patterson Companies Inc	14.68	$ 6,384.837 Millions	$ 434.817 Millions
Neurometrix Inc	14.67	$ 8.229 Millions	$ 0.561 Millions
Ngm Biopharmaceuticals Inc	14.44	$ 58.111 Millions	$ 4.026 Millions
23andme Holding Co	14.39	$ 297.622 Millions	$ 20.686 Millions
Alerislife Inc	14.36	$ 707.966 Millions	$ 49.311 Millions
Travere Therapeutics Inc	14.18	$ 213.399 Millions	$ 15.049 Millions
Corcept Therapeutics Inc	14.15	$ 397.624 Millions	$ 28.095 Millions
Apellis Pharmaceuticals Inc	14.11	$ 113.049 Millions	$ 8.011 Millions

Date modified: 2026-08-29T17:19:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.